AbbVie's Elahere maintains strong efficacy in the Phase 3 MIRASOL trial for ovarian cancer, with durable survival benefits ...

Scientists at King’s College London have developed an innovative IgE antibody therapy that activates the immune system to ...

Glioblastoma has long resisted treatment, but scientists may have found a breakthrough by leveraging the body's own ...

As Colorectal Cancer Awareness Month highlights the importance of early detection and advancements in treatment, according to ...

Jessica Wozniak thought that some of the symptoms of norovirus were lingering. They were signs of Stage 4 colon cancer.

US-based pharmaceutical company AbbVie has reported the final analysis from the Phase III MIRASOL trial, which assessed its ...

Mirvetuximab soravtansine improved overall survival over chemotherapy in patients with FRα-positive, platinum-resistant ovarian cancer.

Researchers have discovered the likely origin of a deadly form of ovarian cancer, offering new hope for early detection and ...

A TROP2-directed antibody-drug conjugate, DB-1305/BNT325, demonstrated durable activity in patients with previously treated ovarian cancer in a first-in-human trial. These results were presented at ...

A new type of antibody which stimulates the immune system to target cancer cells slows tumour growth, according to new research.

Ovarian cancer is the deadliest form of gynecologic cancer, taking the lives of more than 13,000 women in the U.S. each year.

There are three main types of ovarian cancer: epithelial, germ cell, and stromal. Learn about each type’s defining ...